{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"95.6","upperLimit":"97.4","value":"96.5"},{"groupId":"OG001","lowerLimit":"96.6","upperLimit":"98.2","value":"97.4"}]}],"title":"Year 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.0","upperLimit":"92.8","value":"91.4"},{"groupId":"OG001","lowerLimit":"91.2","upperLimit":"93.9","value":"92.6"}]}],"title":"Year 5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.0","upperLimit":"90.2","value":"88.6"},{"groupId":"OG001","lowerLimit":"87.1","upperLimit":"90.3","value":"88.7"}]}],"title":"Year 7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.0","upperLimit":"88.5","value":"86.7"},{"groupId":"OG001","lowerLimit":"84.2","upperLimit":"87.7","value":"85.9"}]}],"title":"Year 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.6","upperLimit":"87.2","value":"85.4"},{"groupId":"OG001","lowerLimit":"83.3","upperLimit":"86.9","value":"85.1"}]}],"title":"Year 10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.9","upperLimit":"86.6","value":"84.7"},{"groupId":"OG001","lowerLimit":"82.5","upperLimit":"86.2","value":"84.4"}]}],"title":"Year 11"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.1","upperLimit":"86.1","value":"84.1"},{"groupId":"OG001","lowerLimit":"81.5","upperLimit":"85.6","value":"83.6"}]}],"title":"Year 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1552"},{"groupId":"OG001","value":"1553"}],"units":"Participants"}],"description":"OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 1 year or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.","id":"OG000","title":"Herceptin 1-Year Arm"},{"description":"Participants who completed definitive surgery and systemic adjuvant chemotherapy received a loading dose of Herceptin as 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks for 2 years or until disease recurrence, whichever occurred first. Participants were observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.","id":"OG001","title":"Herceptin 2-Year Arm"}],"paramType":"NUMBER","populationDescription":"FAS Population 1Y2Y","reportingStatus":"POSTED","timeFrame":"Years 3, 5, 7, 9, 10, 11, 12","title":"OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}